Early treatment is the key to increasing life expectancy for HIV positive.
But huge disparities in the treatment of individuals that could increase a life expectancy for HIV positive
This increase in life expectancy for HIV positive, because it is not, let us say, for all.
It seems that WASPs (rsrs) have a tendency to react better to ART (PQP), lol ....
Well, look at what this text says, which begins, right here:
An American study found that some groups of people with HIV, especially those treated before their CD4 count falls below 350 cells / mm3, now have life expectancies equal to or even higher than the American population at large.
However, the study also found that the life expectancy of the HIV-positive person for some other groups - most notably women and people of other ethnicities than whites - is still considerably low compared to members of the general population and that in people who inject drugs , the life expectancy of the HIV-positive person in the age of antiretroviral therapy (ART) has not improved in any way.
All this leads me to believe that this study was done by WASPs 🙂
A second study, which looked at death rates between both HIV-positive and HIV-negative members of two groups of people at risk of contracting HIV, found that the limit of non-AIDS-defining disease rates among people with HIV who started with ART (the link is almost like chobver in the wet) above 350 cells / mm3 were not, and never were, greater than those among HIV-negative people comparable.
In other words, the only contributor to increasing mortality in people who started early ART was AIDS.
It is very important that you make a difference.
This was not, however, the case in people who started ART later.
They had reduced mortality due to non-AIDS-related causes as well as AIDS.
See treating 'it very important and, as already said to crooked and right. Start immediately.
Life expectancy for HIV positive between , 2000 - 2007 was higher for women
The first study looked at mortality rates between, and then computed the life expectancy of the HIV-positive person to, 22.937 people with HIV in the United States and Canada that started with ART between the beginning of 2000 and the end of 2007. The study then compared their life expectancies at 20 years with that of the general population and noted how it had changed over the eight years of the study.
The life expectancy of the HIV positive person at 20 years in the American population is approximately 57 years in men.
On average, and in the absence of major changes, fifty percent will die around 77 years) and 62 years in women.
And fifty percent chance of death by 82 years. (I think I'll change sex 🙂)
In Canada, men can expect to live approximately three years longer than that and women only two more.
Maybe I'll just move to Canada! (I.e.
The study found that for the group as a whole and beyond the total eight years, the average life expectancy of the HIV-positive person in people with HIV was below 43 years, and fifty percent will die by the 63 years - 15 years earlier than men and 19 years earlier than women of the general American population.
There is a lot of disparity in the life expectancy of HIV-positive people
However, there were life expectancy of the HIV-positive person between the different groups.
While people who inject drugs had an HIV-positive life expectancy of only 29 years older than 20 years, for white people it was 52 years old, for those starting treatment with the CD4 count above 350 cells / mm3 was 55 years old and for gay men it was 57 years old - the same (or slightly larger) than American men in general.
In addition, the life expectancy of the HIV-positive person had improved significantly between 2000 and 2008 for most groups.
In people of ethnicity other than whites, although the life expectancy of the HIV-positive person for those on ART between 2005 and 2007 was still only 48 years older at 20 years - ie nine years behind American men and 14 years ago of American women - this has been a significant improvement since 2000 - 2002. when people of other ethnicities other than whites who were on ART could expect, on average, to die at 50 - a gain of 18 years.
In certain cases Life expectancy for HIV positive is higher than for "normal people."
Life expectancy for HIV positive at 20 years had risen 17 years in men, 10 years in women (although notably, this had not improved since 2005), around 13
years in gay men, around 12,5 years in heterosexual people, and around 20 years in those starting ART in CD4 cell counts above 350 cells / mm3.
This means that the average life expectancy of the HIV-positive person at 20 years was now equal to the American men in the general population, among heterosexual people with HIV, and in white people.
It was also a memorable 69 year at 20 years in gay men and in people starting ART before 350 cells / mm3 - meaning that if nothing else changed these groups, as long as they remained on ART, they have a chance of 50 / 50 of see your 89 anniversary!
WOW !!!!! - Bia P. Say it !!!!!!!!! (I.e.
SEVEN YEARS more than women in the general American population.
Con- stantly, the expectation of an HIV positive person using injecting drug has not improved.
In contrast, the life expectancy of the HIV positive person at 20 years in people who inject drugs had not changed in any way and was still 29 years at 20 years in 2007, as it was in 2000.
Another serious finding was that only 28% of the group had started ART before their CD4 cell count fell
below 350 cells / mm3 although this ratio has improved over time.
Proportionally HIV positive person mortality from non-AIDS-related diseases is higher than in the general population
One of the problems with this type of study is that as not being compared with taste.
HIV Positive person will always have many differences besides their serological status and their medication than the average members of the public, then differences in mortality rate could be attributed to all kinds of other factors.
A second mortality study attempted to approach this by comparing mortality rates in people who, in isolation to their HIV status, were similarly similar.
In doing so, it was possible to achieve the proportion of deaths due to AIDS and thus to find out whether deaths from non-AIDS-related diseases were greater in people with HIV or in ART than in the general population.
Mortality as a result of and non-occurrence of AIDS-related illnesses in HIV-positive persons
This study has observed both mortality and non-AIDS-related mortality in two long-term US study groups - the Multicenter AIDS Cohort Study (MACS) and Women's Interagency HIV Study (WIHS).
These long-term study groups were assembled in 1985 and 1993 respectively. MACS recruited 6972 gay men who were either HIV-positive or at a high risk of contracting HIV infection (41% of participants were already HIV positive at baseline).
And WHIS recruited 4137 women who were either HIV-positive or closely related to HIV-positive women in terms of characteristics (38% of participants were already HIV positive at baseline).
Comparison of mortality in HIV-positive persons and HIV Negative
This study compared mortality rates among members of the HIV-negative and HIV-positive group who were in combination antiretroviral therapy (cART).
As there were no large numbers of cART group members who were either too young or too old, the study only observed "mid-year" mortality between 35 and 70.
For people with HIV the study only observed the mortality subsequent to them starting cART if they were more than 35 years old when they started.
The study looked at mortality until the end of 2010, so some people could be in cART of various types for 15 years or more if they started in the middle of 1990 and had 35 to 55 years at the time.
The average follow-up range was in fact of 10.2 years: 11.7 years with HIV-negative people and 7.6 and 8.1 years (depending on the CD4 count in the initiation of cART) and HIV-positive people in cART.
A high proportion of the group - 60% or 6699 individuals - were included in this study. The first and most obvious fact is that mortality was much higher in people with HIV, as you can expect: over the years 540 2953 people with HIV died (18,2%) compared to 165 3854 HIV negative people (3.4 %). In terms of annual mortality rates, this is 2.32% per year in people with HIV and 0.37% per year in HIV-negative people.
Comparison of non-AIDS related HIV-positive person-related deaths
The researchers then divided the deaths of people with HIV into related and unrelated causes of AIDS: 11.5% of people with HIV died of AIDS and 6.7% of other conditions.
In a specific group, people with HIV knowing that they started cART with a CD4 count greater than 350 cells / mm3, mortality due to non-AIDS-related diseases was not higher than it was in HIV-negative people.
However, even in this group, AIDS deaths predominated, more than doubling mortality (the idea of risking contracting HIV is stupid "), then the overall mortality rate in this group was approximately 1% per year compared to approximately 0.4% in HIV-negative people. This probably reflects the fact that if the Based on the observed mortality rates, they projected the likely future of the mortality rate in people over the age of 70 years. These studies have shown that in people who die from AIDS-related illnesses, they would tend to die much younger. started cART with a CD4 count above 350 cells / mm3 and died of AIDS, there was a chance of 50% dying around the 54 years: in those who died of non-AIDS related diseases, fifty percent was not reached until the age of 75 years, nothing different from HIV-negative people. Thus, people starting ART early were living within the ranges of life expectancy close to n ormal as long as they prevented an early death from AIDS, probably reflecting the widespread improvement in the life expectancy range of the HIV positive person and the vast decrease in the incidence of AIDS in those who survived beyond the beginning of the year 2000.
Low CD4 scores interfere with quality of life and survival
Non-AIDS-related mortality in people who started ART at low CD4 scores, however, was higher than in HIV-negative people. It was 66% higher in people starting cART at CD4 counts between 200 and 350 cells / mm3 and 115% higher in people starting therapy at CD4 counts below 200 cells / mm3, reinforcing the message that initiate ART early and generally better for health, not only because it interrupts AIDS-related diseases. Other factors that increased the chance of death for people in cART were smoking (fifty percent higher the AIDS mortality rate and 120% the higher the non-AIDS mortality rate in smokers); depression (65% is higher than non-AIDS mortality and 58% is higher than AIDS mortality); and high blood pressure (42% is higher than AIDS mortality and 30% higher non-AIDS mortality).
Women in the WHIS study had a 40% mortality rate higher due to non-AIDS diseases than men in the MACS study, but did not have a higher rate due to AIDS.
The greatest influence on non-AIDS mortality was hepatitis B or C co-infection. This more than doubled non-AIDS-related mortality. HIV-negative people with Hepatitis B or C died on average eight years younger than people without, and people with co-infection in cART 15 years younger than those who were HIV-only.
More comparative data is needed
In a separate editorial in the second study, researchers Veronica Miller and Sally Hodder commented that improvements in the life expectancy of the HIV-positive person could be expected to continue in MACS and WHIS. They add that the second study adds considerably to the evidence that early onset antiretroviral therapy; noting that more than 40% of non-AIDS-related deaths and hepatitis were due to cardiovascular disease, and that non-AIDS deaths were higher in people who started ART later. They added that the study continues to beg the question of whether inflammatory processes in people with HIV who are not treated actually add the risk of cardiovascular disease to lower CD4 counts.
Emphasize that the robustness of the study's findings in the life expectancy of the HIV-positive person and cause of death in the study is due to the accumulation of 25 or more years of data, they make a call for continued government support of larger study groups, saying, "Continuous public funds from groups such as MACS, WIHS and others will be much more important as we enter the fourth decade of antiretroviral treatment and seek to improve strategies for improving public and individual health."
This study is also available in Russian.
Well, my last remark in this text, today
One note from me: This minority thing (...) makes me tired. I am, yes, among minorities, because in my birth certificate it is written:
"Color: Brown. "
And what I see is that "minorities", if they do not fight for their rights, die. Fortunately I have Mara because she always fought for me, at a time when I had no strength to fight, given the weakness and even the unconscious and "vegetative" state on one occasion that I was where even "brand step installation " was suggested by doctors, given the bradycardia that they diagnosed and that, in fact, never existed.
This shit happens because some doctors see, in medicine, a gazing to open other's coffers, they are the fluff of the profession. And all they want is to actually enrich themselves with the pain of other people. If you mess with one of these, send them my greetings, because I really want raw tomatoes ... be your best daily meal!
Translated by Rodrigo S. Pellegrni do Otiginal in